OYST logo

Oyster Point Pharma (OYST) EBITDA

Annual EBITDA

-$96.78 M
-$26.34 M-37.39%

December 31, 2021


Summary


Performance

OYST EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

High & Low

Earnings dates

OtherOYSTprofitabilitymetrics:

Quarterly EBITDA

-$33.18 M
+$13.49 M+28.91%

September 30, 2022


Summary


Performance

OYST Quarterly EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

High & Low

Earnings dates

OtherOYSTprofitabilitymetrics:

TTM EBITDA

-$164.01 M
-$16.67 M-11.31%

September 30, 2022


Summary


Performance

OYST TTM EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

High & Low

Earnings dates

OtherOYSTprofitabilitymetrics:

EBITDA Formula

EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization

OYST EBITDA Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1 y1 year-37.4%-101.0%-106.1%
3 y3 years-478.3%-179.0%-246.9%
5 y5 years-1483.3%-395.9%-246.9%

OYST EBITDA Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs lowTTM vs highTTM vs highTTM vs lowTTM vs low
3 y3-yearat highat lowat high+40.7%+69.5%at low
5 y5-year+104.7%at low+114.5%+40.7%+246.9%at low
alltimeall time+1483.2%at low+727.4%+40.7%+2351.2%at low

Oyster Point Pharma EBITDA History

DateAnnualQuarterlyTTM
Sep 2022
-
-$33.18 M(-28.9%)
-$164.01 M(+11.3%)
Jun 2022
-
-$46.67 M(+4.3%)
-$147.34 M(+20.1%)
Mar 2022
-
-$44.75 M(+13.6%)
-$122.65 M(+26.7%)
Dec 2021
-$96.78 M(+37.4%)
-$39.40 M(+138.7%)
-$96.78 M(+21.6%)
Sep 2021
-
-$16.51 M(-24.9%)
-$79.59 M(+0.3%)
Jun 2021
-
-$21.98 M(+16.4%)
-$79.37 M(+8.9%)
Mar 2021
-
-$18.89 M(-15.0%)
-$72.86 M(+2.8%)
Dec 2020
-$70.44 M
-$22.21 M(+36.4%)
-$70.88 M(+3.0%)
Sep 2020
-
-$16.29 M(+5.3%)
-$68.82 M(+6.8%)
DateAnnualQuarterlyTTM
Jun 2020
-
-$15.47 M(-8.5%)
-$64.42 M(+7.0%)
Mar 2020
-
-$16.91 M(-16.1%)
-$60.18 M(+27.3%)
Dec 2019
-$47.28 M(+182.5%)
-$20.15 M(+69.4%)
-$47.28 M(+51.6%)
Sep 2019
-
-$11.89 M(+5.9%)
-$31.18 M(+20.0%)
Jun 2019
-
-$11.23 M(+180.1%)
-$25.98 M(+76.2%)
Mar 2019
-
-$4.01 M(-1.0%)
-$14.75 M(+37.3%)
Dec 2018
-$16.74 M(+173.8%)
-$4.05 M(-39.5%)
-$10.74 M(+60.5%)
Sep 2018
-
-$6.69 M
-$6.69 M
Dec 2017
-$6.11 M
-
-

FAQ

  • What is Oyster Point Pharma annual EBITDA?
  • What is the all time high annual EBITDA for Oyster Point Pharma?
  • What is Oyster Point Pharma annual EBITDA year-on-year change?
  • What is Oyster Point Pharma quarterly EBITDA?
  • What is the all time high quarterly EBITDA for Oyster Point Pharma?
  • What is Oyster Point Pharma quarterly EBITDA year-on-year change?
  • What is Oyster Point Pharma TTM EBITDA?
  • What is the all time high TTM EBITDA for Oyster Point Pharma?
  • What is Oyster Point Pharma TTM EBITDA year-on-year change?

What is Oyster Point Pharma annual EBITDA?

The current annual EBITDA of OYST is -$96.78 M

What is the all time high annual EBITDA for Oyster Point Pharma?

Oyster Point Pharma all-time high annual EBITDA is -$6.11 M

What is Oyster Point Pharma annual EBITDA year-on-year change?

Over the past year, OYST annual EBITDA has changed by -$26.34 M (-37.39%)

What is Oyster Point Pharma quarterly EBITDA?

The current quarterly EBITDA of OYST is -$33.18 M

What is the all time high quarterly EBITDA for Oyster Point Pharma?

Oyster Point Pharma all-time high quarterly EBITDA is -$4.01 M

What is Oyster Point Pharma quarterly EBITDA year-on-year change?

Over the past year, OYST quarterly EBITDA has changed by -$16.67 M (-100.96%)

What is Oyster Point Pharma TTM EBITDA?

The current TTM EBITDA of OYST is -$164.01 M

What is the all time high TTM EBITDA for Oyster Point Pharma?

Oyster Point Pharma all-time high TTM EBITDA is -$6.69 M

What is Oyster Point Pharma TTM EBITDA year-on-year change?

Over the past year, OYST TTM EBITDA has changed by -$84.42 M (-106.06%)